Biomarkers as a bridge — not a substitute — for clinical benefit
In ophthalmic development, imaging biomarkers and fluid analytes can enrich trials and support mechanism-of-action claims, but agencies and payers ultimately weigh functional vision outcomes and patient relevance. Sponsors should define which biomarkers are decision-enabling for internal governance versus which are exploratory.
Imaging charter discipline in retina trials
OCT and angiography readouts are only as credible as acquisition standards and reading center governance. Early investment in imaging charters, training, and quality control reduces attrition in pivotal trials and supports subgroup analyses HTA bodies may request. Inconsistent imaging has delayed more ophthalmic programs than marginal efficacy differences.
Translational plans from early clinical to Phase 3
Phase 1/2 should explicitly test which biomarkers correlate with functional endpoints in the target population. Without that linkage, sponsors risk advancing compounds with beautiful structural signals and ambiguous clinical benefit — a common payer objection at launch.
Subgroup and enrichment strategy
Genetic stratification and disease-severity enrichment can improve power but complicate label and access narratives. Statistical plans should pre-specify how subgroups will be presented to regulators and payers, including multiplicity control and interpretability for medical affairs.
Payer-facing evidence
US and EU payers increasingly request clarity on how imaging changes translate to functional benefit and treatment burden. Integrating biomarker strategy with health economics framing in Phase 2 prevents costly post-hoc analyses after pivotal readout.
Operational recommendation
Treat biomarker and imaging strategy as a cross-functional workstream — clinical, biostatistics, regulatory, and access — with deliverables at protocol finalization, not as a late-stage consulting add-on. BEEÑA-E supports sponsors in designing evidence that satisfies scientific, regulatory, and reimbursement reviewers.
